Cardinal Health (CAH) moved back into focus after reporting strong fiscal third quarter earnings and raising its earnings outlook, which spotlights management’s confidence as the company leans further into specialty pharmaceuticals and radiopharmaceuticals.

Cardinal Health’s recent earnings beat and guidance raise come alongside a 14.07% 30 day share price return and 11.27% year to date share price return. The 1 year total shareholder return of 40.97% and 5 year total shareholder return of 347.52% point to momentum that has been building over several years rather than only in the latest quarter.

If Cardinal Health’s recent move has you reassessing healthcare exposure, it could be a good moment to see what else is gaining attention in 38 healthcare AI stocks

With Cardinal Health trading at $228.91 against a fair value estimate near $245.27 and an indicated intrinsic discount just above 50%, the key question is whether this signals a genuine opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 6.7% Undervalued

Cardinal Health is trading at $228.91 against a narrative fair value of $245.27, which frames the stock as modestly undervalued on analyst assumptions.

The company's investments in automation, advanced supply chain technology, and new distribution centers are expected to deliver long-term operational efficiencies and cost savings, supporting improved net margins and free cash flow as healthcare shifts to value-based and outpatient models.

Read the complete narrative. Read the complete narrative.

Want to understand what sits behind that fair value for Cardinal Health? The narrative leans heavily on steady revenue expansion, slightly improving margins, and a richer future earnings multiple. Curious which specific growth and profitability assumptions make the discount rate of 7.11% still point to upside?

Result: Fair Value of $245.27 (UNDERVALUED)

However, that upside narrative for Cardinal Health still depends on managing tighter government pricing scrutiny and the risk that major customer contracts or reimbursement changes will pressure already thin margins.

Another View: Cardinal Health On Earnings Multiples

While the Cardinal Health narrative points to a fair value of $245.27, the current P/E of 34.5x tells a different story. It sits above the US Healthcare industry at 22.7x and above a fair ratio of 26.9x, which suggests investors are paying a premium that could limit upside if expectations soften.

For a closer look at how those earnings multiples stack up and what that premium might mean in practice, see the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this combination of optimism and concern around Cardinal Health leaves you undecided, take time to review the full balance of data and weigh the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Cardinal Health?

Do not stop at Cardinal Health. Broaden your watchlist with other stocks that fit clear, evidence based themes before the next wave of ideas moves without you.

• Target resilient income by reviewing companies in the 7 dividend fortresses and see which stocks pair yield with underlying business strength.
• Hunt for mispriced quality by scanning the 44 high quality undervalued stocks and compare businesses trading below their assessed worth.
• Prioritise stability by checking the 67 resilient stocks with low risk scores so potential opportunities do not slip past when markets shift.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.